CL2020000283A1 - Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak. - Google Patents
Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak.Info
- Publication number
- CL2020000283A1 CL2020000283A1 CL2020000283A CL2020000283A CL2020000283A1 CL 2020000283 A1 CL2020000283 A1 CL 2020000283A1 CL 2020000283 A CL2020000283 A CL 2020000283A CL 2020000283 A CL2020000283 A CL 2020000283A CL 2020000283 A1 CL2020000283 A1 CL 2020000283A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitors
- compounds
- jak kinases
- triazole compounds
- bicyclic pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCIÓN PROPORCIONA COMPUESTOS DE LA FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, DONDE LAS VARIABLES SE DEFINEN EN LA ESPECIFICACIÓN, QUE SON INHIBIDORES DE QUINASAS JAK, PARTICULARMENTE JAK3. LA INVENCIÓN TAMBIÉN PROPORCIONA FORMAS CRISTALINAS, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS, MÉTODOS PARA USAR DICHOS COMPUESTOS PARA TRATAR ENFERMEDADES INFLAMATORIAS DE TIPO GASTROINTESTINALES Y DE OTRO TIPO, Y PROCESOS Y PRODUCTOS INTERMEDIOS ÚTILES PARA PREPARAR TALES COMPUESTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539642P | 2017-08-01 | 2017-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000283A1 true CL2020000283A1 (es) | 2020-06-12 |
Family
ID=63209687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000283A CL2020000283A1 (es) | 2017-08-01 | 2020-01-31 | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak. |
Country Status (23)
Country | Link |
---|---|
US (4) | US10392368B2 (es) |
EP (1) | EP3652169A1 (es) |
JP (2) | JP7098716B2 (es) |
KR (1) | KR20200036004A (es) |
CN (1) | CN111032646B (es) |
AR (1) | AR112348A1 (es) |
AU (1) | AU2018312349A1 (es) |
BR (1) | BR112020002265A2 (es) |
CA (1) | CA3069990A1 (es) |
CL (1) | CL2020000283A1 (es) |
CO (1) | CO2020001469A2 (es) |
EA (1) | EA038912B1 (es) |
IL (1) | IL272031A (es) |
MA (1) | MA49570A (es) |
MX (1) | MX2020001170A (es) |
MY (1) | MY200629A (es) |
PE (1) | PE20201028A1 (es) |
PH (1) | PH12020500201A1 (es) |
SG (1) | SG11202000602YA (es) |
TW (1) | TW201920150A (es) |
UA (1) | UA125318C2 (es) |
WO (1) | WO2019027960A1 (es) |
ZA (1) | ZA202000561B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200036004A (ko) | 2017-08-01 | 2020-04-06 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물 |
WO2020154350A1 (en) * | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
JP2023528239A (ja) | 2020-05-14 | 2023-07-04 | テラバンス バイオファーマ アールアンドディー アイピー リミテッド ライアビリティ カンパニー | 腸管選択的jak3阻害剤の投与 |
CN114075221A (zh) * | 2020-08-13 | 2022-02-22 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
CN116157388A (zh) * | 2020-09-10 | 2023-05-23 | 四川海思科制药有限公司 | 一种碳环酰胺衍生物及其在医药上的应用 |
WO2022199599A1 (zh) * | 2021-03-23 | 2022-09-29 | 凯复(苏州)生物医药有限公司 | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 |
EP4313974A1 (en) * | 2021-03-29 | 2024-02-07 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
CN113061137B (zh) * | 2021-04-02 | 2022-08-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
WO2022235613A1 (en) * | 2021-05-03 | 2022-11-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
CN116332961A (zh) * | 2021-12-23 | 2023-06-27 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6831094B2 (en) | 2001-04-20 | 2004-12-14 | Wyeth | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
NZ543614A (en) | 2003-05-22 | 2009-09-25 | Abbott Lab | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
US20070104780A1 (en) | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
KR100834758B1 (ko) | 2006-07-05 | 2008-06-05 | 삼성전자주식회사 | 컴퓨터 시스템 보안 장치 및 방법 |
JP2009007342A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
US8536169B2 (en) | 2008-06-05 | 2013-09-17 | Glaxo Group Limited | Compounds |
JP5508400B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
US8653069B2 (en) | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
WO2013149194A1 (en) | 2012-03-29 | 2013-10-03 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
CN103370076A (zh) | 2010-11-02 | 2013-10-23 | 纽约市哥伦比亚大学托管会 | 治疗毛发脱落疾病的方法 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN102993201A (zh) * | 2011-09-14 | 2013-03-27 | 赛诺菲 | 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3,4-b]吡啶-4-羧酸酰胺衍生物 |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
EP2771340B1 (en) | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2788000B1 (en) * | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
EP2847191B1 (en) * | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する1,2,4−トリアジン−6−カルボキサミド誘導体 |
PT3077395T (pt) | 2013-12-05 | 2018-01-03 | Pfizer | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas |
CA2937111A1 (en) | 2014-01-24 | 2015-07-30 | Abbvie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
CN106661039B (zh) * | 2014-02-28 | 2019-09-13 | 林伯士拉克许米公司 | 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途 |
EP3143021B1 (en) | 2014-05-14 | 2019-06-12 | Pfizer Inc | Pyrazolopyridines and pyrazolopyrimidines |
WO2016011394A1 (en) | 2014-07-18 | 2016-01-21 | The General Hospital Corporation | Imaging agents for neural flux |
RU2719446C2 (ru) | 2014-11-03 | 2020-04-17 | Айомет Фарма Лтд | Фармацевтическое соединение |
CN105837574B (zh) | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
EP3288943B1 (en) | 2015-05-01 | 2022-09-28 | Pfizer Inc. | Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase |
JP2018515501A (ja) | 2015-05-07 | 2018-06-14 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨークThe Trustees Of Columbia University In The City Of New York | 発毛を促進する方法及び組成物 |
EP3712152B1 (en) | 2015-11-03 | 2021-01-13 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
AU2017287762C1 (en) | 2016-06-30 | 2020-04-23 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
EP3509572A4 (en) | 2016-09-08 | 2020-05-13 | Synergistic Therapeutics, LLC | TOPICAL FORMULATION FOR HAIR GROWTH |
JP7082120B2 (ja) | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
US20180117148A1 (en) | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
KR20200036004A (ko) | 2017-08-01 | 2020-04-06 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물 |
WO2019090158A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
RS63515B1 (sr) | 2017-12-28 | 2022-09-30 | Daewoong Pharmaceutical Co Ltd | Derivat oksi-fluoropiperidina kao inhibitor kinaze |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
WO2020154350A1 (en) * | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
JP2023528239A (ja) * | 2020-05-14 | 2023-07-04 | テラバンス バイオファーマ アールアンドディー アイピー リミテッド ライアビリティ カンパニー | 腸管選択的jak3阻害剤の投与 |
-
2018
- 2018-07-31 KR KR1020207005956A patent/KR20200036004A/ko not_active Application Discontinuation
- 2018-07-31 AR ARP180102151 patent/AR112348A1/es unknown
- 2018-07-31 UA UAA202001352A patent/UA125318C2/uk unknown
- 2018-07-31 EA EA202090413A patent/EA038912B1/ru unknown
- 2018-07-31 CN CN201880050675.3A patent/CN111032646B/zh active Active
- 2018-07-31 PE PE2020000171A patent/PE20201028A1/es unknown
- 2018-07-31 WO PCT/US2018/044508 patent/WO2019027960A1/en unknown
- 2018-07-31 MX MX2020001170A patent/MX2020001170A/es unknown
- 2018-07-31 AU AU2018312349A patent/AU2018312349A1/en not_active Abandoned
- 2018-07-31 TW TW107126579A patent/TW201920150A/zh unknown
- 2018-07-31 CA CA3069990A patent/CA3069990A1/en not_active Abandoned
- 2018-07-31 JP JP2020505224A patent/JP7098716B2/ja active Active
- 2018-07-31 BR BR112020002265-9A patent/BR112020002265A2/pt not_active Application Discontinuation
- 2018-07-31 MY MYPI2020000251A patent/MY200629A/en unknown
- 2018-07-31 EP EP18755621.2A patent/EP3652169A1/en not_active Withdrawn
- 2018-07-31 SG SG11202000602YA patent/SG11202000602YA/en unknown
- 2018-07-31 MA MA049570A patent/MA49570A/fr unknown
- 2018-07-31 US US16/050,227 patent/US10392368B2/en active Active
-
2019
- 2019-06-28 US US16/456,179 patent/US10538513B2/en active Active
- 2019-11-19 US US16/688,109 patent/US10968205B2/en active Active
-
2020
- 2020-01-14 IL IL272031A patent/IL272031A/en unknown
- 2020-01-27 PH PH12020500201A patent/PH12020500201A1/en unknown
- 2020-01-28 ZA ZA2020/00561A patent/ZA202000561B/en unknown
- 2020-01-31 CL CL2020000283A patent/CL2020000283A1/es unknown
- 2020-02-11 CO CONC2020/0001469A patent/CO2020001469A2/es unknown
-
2021
- 2021-02-22 US US17/249,128 patent/US20220119369A1/en not_active Abandoned
- 2021-03-17 JP JP2021043173A patent/JP2021098751A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PH12020500201A1 (en) | 2020-10-12 |
US20200216423A1 (en) | 2020-07-09 |
CA3069990A1 (en) | 2019-02-07 |
EP3652169A1 (en) | 2020-05-20 |
US20190315724A1 (en) | 2019-10-17 |
IL272031A (en) | 2020-03-31 |
WO2019027960A1 (en) | 2019-02-07 |
TW201920150A (zh) | 2019-06-01 |
US20190040043A1 (en) | 2019-02-07 |
JP2020529987A (ja) | 2020-10-15 |
ZA202000561B (en) | 2022-04-28 |
US10538513B2 (en) | 2020-01-21 |
KR20200036004A (ko) | 2020-04-06 |
AU2018312349A1 (en) | 2020-02-06 |
JP2021098751A (ja) | 2021-07-01 |
AR112348A1 (es) | 2019-10-16 |
SG11202000602YA (en) | 2020-02-27 |
US10968205B2 (en) | 2021-04-06 |
BR112020002265A2 (pt) | 2020-07-28 |
US20220119369A1 (en) | 2022-04-21 |
EA038912B1 (ru) | 2021-11-09 |
CN111032646A (zh) | 2020-04-17 |
JP7098716B2 (ja) | 2022-07-11 |
MX2020001170A (es) | 2020-03-12 |
CN111032646B (zh) | 2023-01-03 |
EA202090413A1 (ru) | 2020-06-24 |
PE20201028A1 (es) | 2020-10-05 |
US10392368B2 (en) | 2019-08-27 |
CO2020001469A2 (es) | 2020-05-29 |
UA125318C2 (uk) | 2022-02-16 |
MY200629A (en) | 2024-01-06 |
MA49570A (fr) | 2020-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000283A1 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak. | |
CL2017002994A1 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
TN2018000043A1 (en) | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors | |
SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
AU2018231032A8 (en) | JAK inhibitors containing a 4-membered heterocyclic amide | |
BR112017000816A2 (pt) | compostos inibitórios terapêuticos | |
UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
CL2018000611A1 (es) | Sales de un inhibidor de pim quinasa | |
CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
CO2017011020A2 (es) | Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k) | |
UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы |